{"url_path":"/sec/fblg/8-k/2026-06-23/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-279778-index.html","accession_number":"0001193125-26-279778","cik":"0001958777","ticker":"FBLG","issuer_name":"FibroBiologics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1958777/0001193125-26-279778-index.html","primary_entity_key":"0001958777","primary_entity_name":"FibroBiologics, Inc."},"word_count":443,"has_tables":true,"body_markdown":"## Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nThe Company held its Annual Meeting on June 22, 2026. Proxies for the Annual Meeting were solicited by the Board pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition. At the Annual Meeting, shares representing 4,174,791 votes were represented in person or by proxy out of the 6,833,915 votes entitled to be cast as of April 24, 2026, the record date for the Annual Meeting. The final votes on the proposals presented at the Annual Meeting were as follows:\n\nProposal No. 1\n\nPete O’Heeron was elected as a Class III director, by a majority of the votes cast and entitled to vote on the election of directors, to hold office until the 2029 Annual Meeting of Stockholders by the following vote:\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n2,795,804\n\n \n\n119,185\n\n \n\n27,511\n\n \n\n1,232,291\n\nIn addition to the director elected above, Richard Cilento, Jr. and Robert E. Hoffman will continue to serve as directors until the 2027 Annual Meeting of Stockholders and Matthew Link and Victoria Niklas, M.D. will continue to serve as directors until the 2028 Annual Meeting of Stockholders, and in each case until their successors are elected and qualified, or until their earlier death, resignation, disqualification or removal. As previously disclosed, Stacy Coen did not stand for re-election to the Board at the Annual Meeting. Accordingly, her term as a Class III director expired at the conclusion of the Annual Meeting.\n\n \n\nProposal No. 2\n\nThe appointment by the Audit Committee of the Board of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the year ending December 31, 2026 was ratified by the following vote::\n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n4,112,372\n\n \n\n43,143\n\n \n\n19,276\n\nProposal No. 3\n\nFor purposes of Nasdaq Listing Rule 5635(d), the issuance of up to 2,272,728 shares of common stock issuable upon the exercise of outstanding common warrants issued pursuant to those certain Securities Purchase Agreements, each dated March 31, 2026, by and among the Company and the purchasers party thereto, or the March SPA, and up to 159,091 shares of common stock issuable upon the exercise of outstanding common warrants issued pursuant to that certain Engagement Letter, dated November 10, 2025, between the Company and H.C. Wainwright & Co., LLC, as amended on March 12, 2026, or the Engagement Letter, in connection with the March SPA, was approved by the following vote::\n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n2,820,710\n\n \n\n97,016\n\n \n\n24,774\n\n \n\n1,232,291\n\nProposal No. 4\n\nThe FibroBiologics, Inc. 2026 Equity and Incentive Compensation Plan was approved by the following vote:\n\n \n\n \n\nFor\n\n \n\nAgainst\n\n \n\nAbstain\n\n \n\nBroker Non-Votes\n\n2,620,158\n\n \n\n297,025\n\n \n\n25,317\n\n \n\n1,232,291"}